Keywords
How to Cite
Abstract
Ushbu tezisda onkologiyada inqilobiy o‘zgarishlarni amalga oshirgan rak immunoterapiyasining zamonaviy yo‘nalishlari va yutuqlari tahli qilinadi. Immunoterapiya – bu bemorning o‘z immunitet tizimini faollashtirish yoki kuchaytirish orqali saraton hujayralarini tanib olish va yo‘q qilish qobiliyatini tiklovchi davolash usulidir. Tezisda ushbu usullarning kimyoterapiya va radiologik davoga nisbatan afzalliklari (uzoq muddatli javob, yon ta'sirlarning nisbatan kamligi), shuningdek, hozirgi cheklovlari (yuqori narx, hamma bemorlarda samara bermaslik, og‘ir autoimmun yon ta'sirlar) ko‘rib chiqiladi. Xulosa qilib, immunoterapiya saraton davolashda yangi davrni ochgan bo‘lsa-da, uning samaradorligini oshirish va yon ta'sirlarni kamaytirish uchun kombinatsiyalashgan yondashuvlar (kimyoterapiya, nishonli terapiya bilan birga) va yangi nishonlarni izlash bo‘yicha tadqiqotlar davom etmoqda.
References
Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61.
2. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355.
3. June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365.
4. Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., ... & Wargo, J. A. (2018). Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 359(6371), 97-103.
5. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., ... & Sznol, M. (2012). Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. *New England Journal of Medicine*, 366(26), 2443-2454.
6. National Cancer Institute (NCI). Immunotherapy to Treat Cancer.
7. American Society of Clinical Oncology (ASCO). Cancer Immunotherapy.